s6y

Tempest Therapeutics, Inc.

Ticker
TPST
CIK
1544227
Industry
Pharmaceutical Preparations
Formerly
Millendo Therapeutics, Inc., OvaScience, Inc.

Financials 61

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K/A Annual Report for period ending Dec 31, 2024
  9. 10-K Annual Report for period ending Dec 31, 2024
  10. 10-Q Quarterly Report for period ending Sep 30, 2024

All 61 financials filings

News 187

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 187 news filings

Ownership 562

  1. 3 Initial statement of beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 3 Initial statement of beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 562 ownership filings

Prospectus 108

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-3 Registration statement for specified transactions by certain issuers
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. S-3 Registration statement for specified transactions by certain issuers
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. S-3 Registration statement for specified transactions by certain issuers
  10. S-8 POS Post-effective amendment to a S-8 registration statement

All 108 prospectus filings

Proxies 47

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEF 14A Definitive proxy statements

All 47 proxies filings

Other 95

  1. ARS Annual report to security holders
  2. D Exempt (Private) Offering
  3. EFFECT Notice of Effectiveness
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. UPLOAD Letter (PDF)
  7. EFFECT Notice of Effectiveness
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. D Exempt (Private) Offering

All 95 other filings